Hologic, Inc. (HO1.F)
- Previous Close
70.00 - Open
70.50 - Bid 71.00 x 10200
- Ask 72.00 x 10000
- Day's Range
70.50 - 70.50 - 52 Week Range
61.18 - 78.66 - Volume
12 - Avg. Volume
4 - Market Cap (intraday)
16.729B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
35.79 - EPS (TTM)
1.97 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
85.50
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
www.hologic.com6,990
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: HO1.F
Performance Overview: HO1.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HO1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HO1.F
Valuation Measures
Market Cap
16.61B
Enterprise Value
17.21B
Trailing P/E
35.49
Forward P/E
18.52
PEG Ratio (5yr expected)
1.40
Price/Sales (ttm)
4.65
Price/Book (mrq)
3.78
Enterprise Value/Revenue
4.34
Enterprise Value/EBITDA
16.19
Financial Highlights
Profitability and Income Statement
Profit Margin
12.98%
Return on Assets (ttm)
6.49%
Return on Equity (ttm)
10.57%
Revenue (ttm)
3.97B
Net Income Avi to Common (ttm)
515.1M
Diluted EPS (ttm)
1.97
Balance Sheet and Cash Flow
Total Cash (mrq)
1.94B
Total Debt/Equity (mrq)
55.40%
Levered Free Cash Flow (ttm)
677.11M
Research Analysis: HO1.F
Company Insights: HO1.F
HO1.F does not have Company Insights